Lilly grants a single compassionate-use request for retatrutide, and Congress asks why

Eli Lilly and the Food and Drug Administration allowed one patient, a 79-year-old man, to receive the experimental obesity drug retatrutide through the FDA's "compassionate use" program in April, according to reporting from STAT that cited three anonymous sources ^[1]. That program is meant to give patients with serious, immediately life-threatening conditions access to treatments still in testing ^[1].

The patient had refractory obesity, obstructive sleep apnea, and pulmonary hypertension, according to STAT's follow-up reporting ^[2]. Sources told STAT the request drew interest from top health officials, which they said suggested the patient was well connected ^[1]. STAT's sources asked not to be named because they feared reprisals ^[1].

Retatrutide is Lilly's next-generation obesity drug, still in clinical testing, that has shown weight loss results comparable to bariatric surgery in trial data ^[1]. It is not yet approved by the FDA, and access outside of clinical trials has been essentially closed to the public.

The unusual grant of access prompted a political response. Sen. Maggie Hassan (D-N.H.) sent a letter to Health and Human Services Secretary Robert F. Kennedy Jr. asking directly whether the patient was President Trump, and requesting documents related to the compassionate use decision ^[2]. Rep. Ted Lieu also raised questions about the case, according to STAT's reporting on the congressional response ^[2]. As of STAT's June 25 report, the identity of the patient had not been confirmed ^[2].

Why it matters for patients

For the much larger group of people managing obesity with approved GLP-1 drugs like Ozempic, Wegovy, Mounjaro, or Zepbound, this episode does not change access to those medications. But it does highlight how narrow and discretionary the compassionate use pathway is for drugs still in testing, such as retatrutide. Only patients who meet a serious, life-threatening standard and who apply through the FDA and the drugmaker are eligible, and Lilly has historically granted such requests rarely.

The controversy also raises fairness questions that matter to ordinary patients waiting for retatrutide's eventual approval. If special access can be granted to one person under circumstances that draw scrutiny from lawmakers, patients and advocates may reasonably ask how such decisions get made, and whether the process is applied consistently. STAT's sources described the interest of "top health officials" in this single case, which is not typical for compassionate use requests ^[1].

None of the sources reviewed confirm details of a formal, broader application process for retatrutide compassionate use, including eligibility criteria, timing, or how many additional patients might be considered. That information is not yet known from the reporting available.

What happens next

As of June 25, 2026, Sen. Hassan's letter to HHS Secretary Kennedy was seeking documents and an explanation from the administration, and the identity of the patient remained unconfirmed in STAT's reporting ^[2]. Whether HHS or Lilly will respond publicly to the congressional inquiry, and what any broader access process might look like, are not detailed in the sources reviewed here.